Condition
Limited-stage Small Cell Lung Cancer (LS-SCLC) clinical trials and research
Research outlook What's coming for Small cell lung cancer: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 4 Limited-stage Small Cell Lung Cancer (LS-SCLC) clinical trials that are recruiting, at sites in 6 countries (most in China (4), Georgia (1), Netherlands (1)). By phase: Phase 2 (2), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 6Countries
Newest Limited-stage Small Cell Lung Cancer (LS-SCLC) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| QL1706 with chemotherapy induction followed by immunotherapy consolidation in limited-stage SCLC after chemoradiotherapy | Phase 2 | Shanghai | Recruiting | Jul 29, 2025 |
| Predicting response to immunotherapy in small cell lung cancer after chemotherapy and radiotherapy | — | Beijing, Beijing Municipality | Recruiting | Mar 11, 2025 |
| Combining chemotherapy and immunotherapy for limited-stage small cell lung cancer | Phase 2 | Guangzhou, Guangdong | Recruiting | Dec 6, 2024 |
| Using toripalimab alone or with tifcemalimab for treating limited-stage small cell lung cancer | Phase 3 | Harbin, Heilongjiang and 75 other locations | Recruiting | Oct 23, 2023 |
All recruiting trials (4)
-
QL1706 with chemotherapy induction followed by immunotherapy consolidation in limited-stage SCLC after chemoradiotherapy
This study tests if QL1706 given with chemotherapy induction can improve outcomes for adults with limited-stage small cell lung cancer after chemoradiation, with follow-up immunotherapy consolidation and biomarker analysis.
-
Predicting response to immunotherapy in small cell lung cancer after chemotherapy and radiotherapy
This study is testing if a new maintenance therapy using a PD-L1 inhibitor can improve treatment outcomes for patients with limited-stage small cell lung cancer after they’ve had chemotherapy and radiotherapy.
-
Combining chemotherapy and immunotherapy for limited-stage small cell lung cancer
This study is testing a new treatment that combines chemotherapy and immunotherapy to see if it can help people with limited-stage small cell lung cancer live longer and feel better.
-
Using toripalimab alone or with tifcemalimab for treating limited-stage small cell lung cancer
This study is testing if a new combination of two drugs can help people with limited-stage small cell lung cancer feel better after their initial treatment.
Related topics
Quick answers
How many Limited-stage Small Cell Lung Cancer (LS-SCLC) clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 6 countries. The most sites are in China (4 trials), Georgia (1 trial), Netherlands (1 trial), Spain (1 trial), Taiwan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.